Combining the Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Provides a Comprehensive Prognostic Model for CD34-Selected Allogeneic HCT
Year: 2017
Type: article
Abstract: Introduction: T-cell depletion (TCD) by positive CD34+ selection correlates with reduced incidence and severity of GvHD. A national phase 3 trial (BMT CTN 1301) is currently evaluating CD34+ selection as one of three randomized treatment assignments to evaluate GvHD, RFS, and OS. As HCT-CI informs outcomes after TCD allogeneic HCT (allo HCT), we evaluated HCT-CI in conjunction with disease risk index (DRI) to validate a comprehensive prognostic model.
Authors: Christina Cho, Patrick Hilden, Scott T. Avecilla, Juliet N. Barker, Hugo Castro-Malaspina, Sergio A. Giralt, Ann A. Jakubowski, Guenther Koehne, Molly Maloy, Richard Meagher, Richard J. O'Reilly, Esperanza B. Papadopoulos, Jonathan U. Peled, Doris M. Ponce, Roni Tamari, Marcel R.M. van den Brink, James W. Young, Pere Barba, Miguel-Angel Perales
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2590893702